Passage BIO (PASG) Operating Expenses (2019 - 2026)
Passage BIO (PASG) posted quarterly Operating Expenses of $8.9 million for Q1 2026, down 35.75% year-over-year from $13.8 million in Q1 2025, and down 14.12% quarter-over-quarter from $10.3 million in Q4 2025.
Passage BIO (PASG) Operating Expenses (2019 - 2026) Analysis & Trends
Passage BIO's Operating Expenses history runs 8 years deep, the most recent figure standing at $8.9 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 35.75% year-over-year to $8.9 million; the TTM figure through Mar 2026 stood at $38.2 million (down 37.3% YoY), while the FY2025 annual figure was $43.2 million, down 33.78% from the prior year.
- Operating Expenses for Q1 2026 stood at $8.9 million, down from $10.3 million in the prior quarter.
- The five-year high for Operating Expenses was $41.3 million in Q1 2022, with the low at $8.7 million in Q3 2025.
- The 5-year median for Operating Expenses is $18.0 million (2024), against an average of $20.9 million.
- The sharpest annual moves came in 2022 and 2024: Operating Expenses rose 10.36% in 2022, then sank 49.7% in 2024.
- Passage BIO's Operating Expenses stood at $28.2 million in 2022, then tumbled by 34.69% to $18.4 million in 2023, then slipped by 22.64% to $14.3 million in 2024, then fell by 27.54% to $10.3 million in 2025, then slipped by 14.12% to $8.9 million in 2026.
- Business Quant data shows PASG's Operating Expenses at $8.9 million in Q1 2026, $10.3 million in Q4 2025, and $8.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Passage BIO | 15.05 Mn | 15.05 Mn | - | 10.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.22 Mn |
| Mar 31, 2026 | 8.88 Mn |
| Dec 31, 2025 | 10.34 Mn |
| Sep 30, 2025 | 8.66 Mn |
| Jun 30, 2025 | 10.33 Mn |
| Mar 31, 2025 | 13.82 Mn |
| Dec 31, 2024 | 14.27 Mn |
| Sep 30, 2024 | 15.91 Mn |
| Jun 30, 2024 | 16.94 Mn |
| Mar 31, 2024 | 18.05 Mn |
| Dec 31, 2023 | 18.45 Mn |
| Sep 30, 2023 | 23.28 Mn |
| Jun 30, 2023 | 25.39 Mn |
| Mar 31, 2023 | 35.88 Mn |
| Dec 31, 2022 | 28.24 Mn |
| Sep 30, 2022 | 26.03 Mn |
| Jun 30, 2022 | 39.81 Mn |
| Mar 31, 2022 | 41.31 Mn |
| Dec 31, 2021 | 50.16 Mn |
| Sep 30, 2021 | 41.60 Mn |